USE OF STEM CELLS FOR WOUND HEALING
Cells, compositions, and methods of cell therapy for administering a therapeutically effective amount of stem cells or cell concentrate to achieve accelerated wound healing of normal and chronic wounds, while minimizing the formation of scar tissue.
1 . An isolated cell population comprising:
differentiated mesenchymal stem cells having myofibroblast-like characteristics wherein the stem cells are differentiated through exposure to one or more communication molecules from a keratinocyte conditioned medium.
2 . The isolated cell population of claim 1 wherein the differentiated mesenchymal stem cells are differentiated human mesenchymal stem cells.
3 . The isolated cell population of claim 1 wherein the differentiated mesenchymal stem cells are a differentiated bone marrow derived human mesenchymal stem cells.
4 . The isolated cell population of claim 1 wherein the differentiated mesenchymal stem cells are differentiated autologous mesenchymal stem cells.
5 . The isolated cell population of claim 1 wherein the mesenchymal stem cells are differentiated through exposure with one or more communication molecules for approximately 10-30 days.
6 . The isolated cell population of claim 1 wherein the communication molecules are selected from the group consisting of IL-6, IL-8, VEGF, SDF-1, CXCL5, and combinations thereof.
7 . The isolated cell population of claim 1 wherein the differentiated mesenchymal stem cells exhibit at least one cytoskeletal marker associated with a myofibroblast cell type.
8 . The isolated cell population of claim 7 wherein the cytoskeletal marker is selected from the group consisting of α-smooth muscle actin, vinculin, vimentin, F-actin, fibroblast surface protein and combinations thereof.
9 . The isolated cell population of claim 7 wherein at least 29% of the differentiated mesenchymal stem cells express α-smooth muscle actin.
10 . The isolated cell population of claim 7 wherein at about 75% of the differentiated mesenchymal stem cells express α-smooth muscle actin.
11 . The isolated cell population of claim 1 wherein the differentiated mesenchymal stem cells express one or more cytokines associated with a myofibroblast cell type.
12 . The isolated cell population of claim 11 wherein the cytokines are selected from the group consisting of IL-6, IL-8, SDF-1, CXCL5, VEGF, MMP1, CXCL6, COL4A4, MMP13, CYP7B1, ADAMDEC1, SLC6A1, CXCL1, PF4V1, CXCL3, CH25H, SFRP2, DARC, HCK, ERC2, CLIC6, BCL8 and combinations thereof.
13 . The isolated cell population of claim 11 wherein the differentiated mesenchymal stem cells exhibit expression of about 0.0-2,300.0 pg/ml of each of the one or more cytokines.
14 . The isolated cell of claim 11 wherein the differentiated mesenchymal stem cells exhibit expression of between 800.0-900.0 pg/ml of IL-6.
15 . The isolated cell of claim 11 wherein the differentiated mesenchymal stem cells exhibit expression of between 450.0-2,300.0 pg/ml of IL-8.
16 . The isolated cell of claim 11 wherein the differentiated mesenchymal stem cells exhibit expression of between 1,600.0-2,300.0 pg/ml of VEGF.
17 . The isolated cell of claim 11 wherein the differentiated mesenchymal stem cells exhibit expression of between 225.0-1,300.0 pg/ml of SDF-1.
18 . A method for differentiating a stem cell into a cell exhibiting myofibroblast-like properties comprising:
isolating one or more mesenchymal stem cells within a population of stem cells;
exposing the mesenchymal stems cells to one or more communication molecules from a keratinocyte conditioned medium; and
differentiating the mesenchymal stem cells into a myofibroblast-like cell.
19 . A method for healing a wound in a patient comprising:
isolating a population of mesenchymal stem cells;
differentiating the mesenchymal stem cells into myofibroblast-like cells; and
administering a therapeutically effective amount of the differentiated mesenchymal stem cells to a wound site.
20 . A method for healing a wound in a patient comprising:
isolating a population of mesenchymal stem cells;
exposing the population of mesenchymal stem cells to one or more communication molecules from a keratinocyte conditioned medium;
differentiating the mesenchymal stem cells into myofibroblast-like cells; and
administering a therapeutically effective amount of the differentiated mesenchymal stem cells to a wound site.
21 - 42 . (canceled)
43 . A method for healing a wound in a patient comprising:
isolating a population of mesenchymal stem cells; and
administering a therapeutically effective amount the mesenchymal stem cells to a wound site.
44 . A composition for healing a wound in a patient comprising:
a cell lysate prepared from a population myofibroblast-like cells derived from mesenchymal stem cells wherein the mesenchymal stem cells were differentiated into myofibroblast-like cells from exposure to one or more communication molecules from a keratinocyte conditioned medium.
45 . A composition for healing a wound in a patient comprising:
a cell lysate prepared from a population mesenchymal stem cells.
46 - 51 . (canceled)
52 . A method for healing a wound in a patient comprising:
isolating a population of mesenchymal stem cells;
differentiating the mesenchymal stem cells into myofibroblast-like cells;
isolating a cell lysate of the myofibroblast-like cells; and
administering a therapeutically effective amount of the cell lysate to a wound site.
53 . A method for healing a wound in a patient comprising:
isolating a population of mesenchymal stem cells;
isolating a cell lysate of the mesenchymal stem cells; and
administering a therapeutically effective amount of the cell lysate to a wound site.
54 - 63 . (canceled)